Dossier · BSIN · Dormant
BSIN · Big Sky Industrial Inc. · Stock research
Last analysed ·
Current thesis
BSIN — research research dossier: thesis, invalidation trigger, archetype.
Current Thesis
_(no analysis yet — pending first synthesis or watchlist research)_
Bullish and bearish views on Big Sky Industrial Inc.
Bull Case
_(pending)_
Bear Case
_(pending)_
Setup & Price Structure
_(pending)_
Catalyst Calendar (next 30 days)
_(pending)_
What Would Change Our Mind
_(pending)_
Correlation Notes
_(pending)_
Related · shared themes
HNGE
Hinge Health, Inc.
Digital-MSK profitability re-rate broke out in May and was pushed into open price discovery by the 2026-06-09 mid-quarter raise (Q2 to $200–202M, +45%; FY26 to $818–824M). But nine sell-side target hikes in two weeks plus accelerating insider selling mark a late, distribution-prone phase, with no company catalyst until the ~2026-08-04 Q2 print.
BFLY
Butterfly Network, Inc.
Butterfly Embedded chip-licensing story got marquee validation Midjourney's up-to-$74M/5yr full-body scanner on 40 Ultrasound-on-Chip modules (2026-06-18) plus 2nd partner Aleph Neuro (2026-06-25). Fundamentals still accelerating, but the June double has stalled and news thinned; a binary Q2 print (~early Aug) is now the next input and the easy momentum leg is spent.
PSNL
Personalis, Inc.
The MRD story has been overtaken by a live sale process: StreetInsider reported 2026-07-17 that Personalis retained Centerview, TD Securities and Cooley after takeover interest from Merck (already a >10% holder and 19% of Q1 revenue) plus two other suitors. Price broke to a $16.39 52-week high; Needham $17 and TD Cowen $18 now sit above the tape. Aug-4 Q2 is the next hard date.
GH
Guardant Health, Inc.
Blood-based CRC screening narrative still accelerating: a second July cluster of PT raises pushed the Street high to $215 (Citi, 7/8), ~$40 — above June's $175 peak. GH is the theme leader re-rating higher, but the only fuel before the ~early-August Q2 print is positioning into an earnings binary.